Differential immunomodulatory effect of PARP inhibition in BRCA1 deficient and competent tumor cells
Isabel Alvarado-Cruz(University of Arizona), Joann B. Sweasy(Susan Thompson Buffett Foundation), Daniel J. Laverty(Massachusetts Department of Public Health), Yong Kong(W. M. Keck Foundation), Michael Krauthammer(University of Zurich), Mohammed Imran Khan(New York University), Rithy Meas(University of Arizona), Kurt A. Schalper(Yale University), Hailey Wyatt(Yale University), Ying Zhu(National Clinical Research Center for Digestive Diseases), Kaylyn Clairmont(Yale University), Angelo Porciuncula(Yale University), Yu Shyr(Vanderbilt University), Patricia LoRusso(Yale Cancer Center), Shuangge Ma(Yale University), Sebastian Oeck(Essen University Hospital), Victoria Quintana(University of Arizona), Zachary D. Nagel(Harvard University), Shilin Zhao(Vanderbilt University Medical Center), Mariam M. Mahmoud(Yale University)
Cited by 11
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
|The Lancet Oncology|2012|1.3k
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis
|Cancer Cell|2004|1.1k
Regularized gene selection in cancer microarray meta-analysis
|BMC Bioinformatics|2009|839
Programmed death ligand-1 expression in non-small cell lung cancer
|Laboratory Investigation|2013|753